多西他赛联合卡铂治疗晚期非小细胞肺癌的临床研究

Clinical research on docetaxel with carboplatin in the treatment of advanced non-small cell lung cancer patients

目的观察国产多西他赛联合卡铂治疗晚期非小细胞肺癌的临床疗效和毒副反应。方法53例晚期非小细胞肺癌患者均经细胞学或组织学证实,所有患者均进行多西他赛联合卡铂方案化疗,其中多西他赛75 mg/m2静脉滴注,第1天;卡铂AUC=5 mg/(ml.min),静脉滴注,第1天;21天为1周期,化疗两周期评价一次疗效。每例患者至少接受二个疗程化疗。结果全组53例患者均可评价疗效,完全缓解(CR)2例,部分缓解(PR)22例,稳定(SD)20例,疾病进展(PD)9例,总有效率为45.3%。其中初治患者28例,CR+PR 16例,有效率57.1(;复治25例,PR 8例,有效率32.0%。毒性反应主要有骨髓抑制和胃肠道反应,疲乏,脱发,口腔粘膜炎。结论多西他赛联合卡铂方案是治疗晚期非小细胞肺癌较为理想的方案之一。

Objective To investigate the clinical efficacy and side effects of domestic docetaxel with carboplatin in advanced non-small cell lung cancer（NSCLC） patients. Methods All 53 cases with NSCLC were identified by cytological or histological methods and treated with docetaxel（75mg/m2 ivgtt d1） and carboplatin（AUC=5mg/（ml﹒min）,iv d1） for 3 weeks as a cycle.Results Two cases of complete remission（CR）,22 cases of partial remission（PR）,20 cases of stable disease（SD） and 9 cases of progressive disease（PD） were achieved in all of the 53 cases.The response rate（CR＋PR） was 45.3% of the previously in-treated 28 patients and 30% previously treated group respectively with overall response rate was 57.1%.Significant difference was observed between the two groups（P〈0.05）.The main side effects were digestive tract reaction and myelosuppression.Conclusions Docetaxel combined with carboplatin maybe one of the best regimens in the treatment of patients with advanced NSCLC.